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ARTICLE IN PRESS
CLINICAL RESEARCH STUDY
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ABSTRACT
PURPOSE: We conducted this study to investigate the association of cardiorespiratory fitness and all-cause
mortality among patients with chronic kidney disease.
METHODS: We studied a retrospective cohort of patients from the Henry Ford Health System who underwent clinically indicated exercise stress testing with baseline cardiorespiratory fitness and estimated glomerular filtration rate measurement. Cardiorespiratory fitness was expressed as metabolic equivalents of
task, and kidney function was categorized into stages according to estimated glomerular filtration rate.
Multivariable-adjusted Cox proportional hazard models were used to examine the association between
metabolic equivalents of task and all-cause mortality among patients with chronic kidney disease stages 35. Discrimination of mortality was assessed using receiver operating characteristic curves, while reclassification was evaluated using net reclassification index (NRI).
RESULTS: Among 50,121 participants, the mean age was 55 § 12.6 years; 47.5% were women, 64.5%
were white, and 6877 (13.7%) participants had chronic kidney disease stage 3-5. Over a median follow-up
of 6.7 years, 6308 participants died (12.6%). Each 1-unit higher metabolic equivalents of task was associated with a significant 15% reduction in all-cause mortality (hazard ratio 0.85; 95% confidence interval
[CI], 0.84-0.87). Metabolic equivalents of task improved discriminatory ability of mortality prediction
when added to traditional risk factors and estimated glomerular filtration rate (area under the curve
0.7996; 95% CI, 0.789-0.810 vs 0.759; 95% CI, 0.748-0.770, respectively; P < .001). The addition of metabolic equivalents of task to traditional risk factors resulted in significant reclassification (6% for events,
5% for non-events: NRI = 0.13, P < .001).
CONCLUSIONS: Cardiorespiratory fitness improves mortality risk prediction among patients with chronic
kidney disease. Cardiorespiratory fitness provides incremental prognostic information when added to traditional risk factors and may help guide treatment options among patients with renal dysfunction.
Ó 2021 Elsevier Inc. All rights reserved.  The American Journal of Medicine (2021) 000:1−9
KEYWORDS: Cardiorespiratory fitness; Chronic kidney disease
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INTRODUCTION

METHODS

Chronic kidney disease, which affects 10%-13% of the US
Study Cohort
population, is universally regarded as a major contributor to
The Henry Ford Exercise Testing Project (FIT Project) is a
health care costs through significant effects on morbidity
retrospective cohort study that examined the long-term
and mortality.1,2 Renal dysfunction predisposes patients to
prognostic implications of cardiorespiratory fitness in an
adverse cardiovascular disease outcomes through multiple
ethnically diverse cohort. The FIT Project consists of
pathophysiologic pathways. How69,885 patients who underwent
ever, widely used cardiovascular
physician-referred treadmill stress
disease risk calculators may not be CLINICAL SIGNIFICANCE
testing between 1991 and 2009.
well calibrated in this patient popu Higher cardiorespiratory fitness is Study details have been previously
lation, as individuals with chronic
20
associated with a lower adjusted risk of described. The FIT project was
kidney disease were not well represented in the derivation cohorts
all-cause mortality across the spectrum approved by the Henry Ford Hospital Institutional Review Board.
used to construct these risk calculaof chronic kidney disease stages.
tors. The addition of estimated glo Cardiorespiratory fitness improves mormerular filtration rate and albumintality risk discrimination and reclassifi- Exclusion Criteria
to-creatinine ratio to traditional carcation when added to traditional Patients were excluded if they were
diovascular disease risk factors in
<18 years old or if the testing protocardiovascular risk factors.
patients with chronic kidney disease
 Cardiorespiratory fitness may provide col was not the standard Bruce prohas been shown to improve the preimportant prognostic information tocol. We further excluded patients
dictive accuracy of cardiovascular
among patients with chronic kidney who had a history of heart failure
disease events.3,4 Therefore, addi(defined as prior clinical diagnosis
disease.
tional efforts are needed to identify
of systolic or diastolic heart failure;
novel risk factors to refine prognosn = 1579) and patients missing reletication in this patient population.
vant covariate data, including creatCardiorespiratory fitness is an objective physiologic
inine (n = 17,434) or metabolic equivalents of task (n = 751).
measure that describes the capacity of an individual’s circulatory and respiratory systems to transport and utilize oxygen in the metabolically active skeletal muscle during
Assessment of Outcomes
exercise. Importantly, it is an integrative measure influenced by several factors including physical activity habits,
The primary end point of our analysis was all-cause mortalobesity, genetics, and traditional risk factors. Over the past
ity, which was verified through the Social Security Death
4 decades, numerous studies have demonstrated a favorable
Index master file using each patient’s social security numeffect of cardiorespiratory fitness on long-term adverse outber, first name, last name, and date of birth. The annualized
comes.5-12 Higher cardiorespiratory fitness is associated
mortality rate for each group was calculated by dividing the
with a reduction in cardiovascular disease risk factors,
observed mortality rate during the follow-up duration by
major adverse cardiac events, and overall mortality.13,14
the mean follow-up time for the group. Secondary outcomes
Prior studies have shown that exercise leads to improved
included major adverse cardiac events (defined as myocarfunctioning in patients with chronic kidney disease.15-18
dial infarction or revascularization), which were ascertained
Poor cardiorespiratory fitness among patients with renal
through June 2010 using administrative claims files from
dysfunction is independently associated with a high burden
services delivered by the affiliated group practice or reimof cardiovascular risk factors in addition to increased aortic
bursed by the health plan. Linkage was performed using relstiffness, increased left ventricle afterload, and poor left
evant International Statistical Classification of Diseases and
ventricular function, providing a milieu of increased overall
Related Health Problems, ninth revision (410.xx). To minicardiovascular risk.19
mize bias from loss to follow-up, patients were censored at
To date, little is known about the prognostic significance
their last contact with the Henry Ford Health System when
of cardiorespiratory fitness in patients with chronic kidney
ongoing coverage with the health plan could no longer be
disease. We aimed to evaluate the prognostic value of carconfirmed.
diorespiratory fitness for predicting mortality among
patients with renal dysfunction. We hypothesized that carTreadmill Stress Testing and Metabolic
diorespiratory fitness would provide incremental value to
Equivalents of Task
traditional risk factors in predicting mortality in this highrisk patient population. As chronotropic incompetence may
All patients underwent clinically indicated, symptom-limcontribute to low cardiorespiratory fitness, we also examited maximal treadmill stress testing following the standard
ined the interrelationship between chronotropic incompeBruce protocol and administered by clinical exercise physitence and cardiorespiratory fitness among patients with
ologists or registered nurses. For individuals with repeat
chronic kidney disease.
stress testing during the data collection period, only the
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on October 18, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

Chu et al

ARTICLE IN PRESS

Chronic Kidney Disease and Cardiorespiratory Fitness

results of the first test were included. Patients undergoing
pharmacological stress testing, modified Bruce, and other
non-Bruce protocol tests were excluded. In accordance with
American Heart Association and American College of Cardiology guidelines, tests were terminated at the discretion
of the supervising clinician for potentially life-threatening
reasons (significant arrhythmias, abnormal hemodynamic
responses, diagnostic ST-segment changes, exercise-limiting symptoms such as chest pain or shortness of breath) or
if the patient was unable to continue.
Cardiorespiratory fitness was estimated using metabolic
equivalents of task based on the workload derived from the
maximal speed and grade achieved during the treadmill
time. Metabolic equivalents of task were categorized as <6,
6 to 10, 10 to 12, and >12 because these cut-off points best
represent the distribution of cardiorespiratory fitness in the
FIT database and have been shown in prior studies to be
associated with incident adverse outcomes.8,21,22 Failure to
achieve target heart rate was defined as not achieving
≥85% of maximum predicted heart rate.

Assessment of Renal Function
Creatinine measurements were collected from the electronic medical record and laboratory databases. For each
patient, the test conducted closest to the date of the stress
test was selected for inclusion. The median time difference
between stress testing and creatinine measurement was
22 days (interquartile range 5-71 days). Estimated glomerular filtration rate was calculated using the Levey Modification of Diet in Renal Disease formula: estimated
glomerular filtration rate = 175 * standardized serum
creatinine 1.154 * age 0.203 * 1.212 (if black) * 0.742
(if female). The calculated glomerular filtration rate values
were categorized as ≥90 mL/min per 1.73 m2 (stage 1), 60
to 89 mL/min per 1.73 m2 (stage 2), 30 to 59 mL/min per
1.73 m2 (chronic kidney disease stage 3), and <30 mL/min
per 1.73 m2 (stage 4/5), based on the Kidney Disease Outcomes Quality Initiative classification of kidney function.23
Renal insufficiency was defined as chronic kidney disease
stage 3 or greater.

Assessment of Covariates
Details on medical history including age, sex, race, anthropomorphic data, cardiovascular risk factors, past medical
history, and active medication use were obtained by nurses
or exercise physiologists immediately prior to stress testing.
Diabetes mellitus was defined as a previous diagnosis of
diabetes, use of hypoglycemic medications, or a databaseverified diagnosis of diabetes. Dyslipidemia was defined by
a previous diagnosis of any major lipid abnormality, use of
lipid-lowering medications, or a database-verified diagnosis
of dyslipidemia. History of coronary artery disease was
defined as previous myocardial infarction, percutaneous
coronary intervention, coronary artery bypass surgery, or
previous documented obstructive coronary heart disease by
angiogram. Body mass index was calculated as weight in

3

kilograms divided by height in meters squared and categorized as <18.5, 18.5-24.9, 25-29.0, and >30 kg/m2.

Statistical Analysis
Baseline characteristics were stratified by chronic kidney
disease stage. Categorical data were presented as percent
frequencies and compared between groups by chi-squared
testing. Continuous variables were presented as mean §
standard deviation and compared using Student’s t test.
Non-normally distributed variables were presented as
median and 25th to 75th interquartile rages and were compared using nonparametric test (Mann-Whitney test).
Kaplan-Meier curves were constructed to graphically
demonstrate the cumulative survival all-cause mortality and
major adverse cardiovascular events, stratified by chronic
kidney disease stages and achieving target heart rate. After
confirming the proportionality assumption using Schoenfeld residuals, multivariable-adjusted Cox proportional hazard adjusted models were used to study the association
between metabolic equivalents of task (modeled as categorical or continuous) and all-cause mortality. Model 1 was
adjusted for age, sex, and race. Model 2 was additionally
adjusted for hypertension, diabetes, dyslipidemia, body
mass index categories, history of coronary artery disease,
history of smoking, statin use, aspirin use, beta-blocker use,
failure to achieve target heart rate, and estimated glomerular filtration rate.
Improvement in risk discrimination of incident outcomes
was assessed using area under receiving operating characteristic curves (AUC) based on Cox models. The base
model (Model 1) was adjusted for age, sex, race, hypertension, diabetes, dyslipidemia, body mass index categories,
history of coronary artery disease, history of smoking, statin
use, and aspirin use. Model 2 was additionally adjusted for
estimated glomerular filtration rate and Model 3 was additionally adjusted for metabolic equivalents of task. We calculated the P value comparing Model 1 and 2 C-statistics
and comparing Model 1 and 3 C-statistics. Improvement in
reclassification was assessed using the net reclassification
index (NRI) for the addition of metabolic equivalents of
task to age, sex, race, hypertension, diabetes, dyslipidemia,
body mass index categories, history of coronary artery disease, history of smoking, statin use, and aspirin use.
Additional sensitivity analyses were conducted to determine the robustness of our results. 1) We expanded our definition of chronic kidney disease to include stages 2 to 5. 2)
We evaluated the association between metabolic equivalents of task and all-cause mortality stratified by each
chronic kidney disease stage and performed multiplicative
interaction testing between metabolic equivalents of task
and chronic kidney disease stages to assess for effect modification. 3) We evaluated the association between failure to
achieve target heart rate and all-cause survival adjusting for
age, sex, race, hypertension, diabetes, dyslipidemia, body
mass index categories, history of coronary artery disease,
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history of smoking, statin use, aspirin use, beta-blocker use,
glomerular filtration rate, and metabolic equivalents of task.
A P value < .05 was considered statistically significant.
Statistical analyses were performed using SPSS (version
21.0; IBM Inc., Chicago, III) and STATA (IC Version 16;
StataCorp, College Station, Texas). The analyzing software
considered the correlated estimates of the model performance, given that the same dataset was used for comparison
of the concordance statistics and in calculating the AUC. Of
note, AUC for time-dependent receiver operating characteristic analysis has also been utilized successfully in several
other publications.24

RESULTS
Baseline Characteristics
A total of 50,121 patients (mean age 55 § 13 years, 48%
female, and 29% black) were included in the analysis. Baseline characteristics of the study cohort are summarized in
Table 1

Table 1. Patients in higher chronic kidney disease stages
were more often women, white, and a had a high burden of
cardiovascular risk factors including diabetes mellitus,
hypertension, hyperlipidemia, and prior myocardial infarction (P < .001). The prevalence of cardioprotective medication use including cholesterol-lowering agents, betablockers, aspirin, diuretics, angiotensin-converting enzyme
inhibitors, and aldosterone receptor blockers was higher
among patients with higher chronic kidney disease stages
(P < .001) (Table 2).

Outcomes
Over a median follow-up period of 6.7 years (25th to 75th
percentiles; 3.9 to 10 years), 6308 patients (12.6%) died.
The rate of death increased with worsening renal function,
with the highest percentage seen in those with advanced
renal disease (annualized death rate = 1.4%, 1.6%, 3.7%,
and 9.8% for chronic kidney disease stage 1, 2, 3, and 4/5,
respectively, P < .001).

Baseline Characteristics of the Study Cohort According to Chronic Kidney Disease Stages
Chronic Kidney Disease
Total

Stage 2 CKD eGFR 6089 mL/min/1.73 m2
30,254 (60.4)

Stage 3 CKD eGFR 3059 mL/min/1.73 m2
6449 (12.9)

Stage 4/5 CKD eGFR
< 30 mL/min/1.73 m2
428 (0.9)

54 (46, 64)
50 (41, 56)
23,790 (47.5) 6189 (47.6)

55 (48, 64)
13,993 (46.3)

65 (55, 73)
3418 (53)

62 (51, 72)
190 (44.4)

32,342 (64.5)
14,329 (28.6)
3450 (6.9)
28.7 (25, 33)
73 § 12.6

6049 (46.6)
5899 (45.4)
1042 (8)
29.3 (26, 34)
74 (§ 12.7)

21,225 (70.2)
6968 (23)
2061 (6.8)
28.6 (25, 32)
72 (§ 12.5)

4875 (75.6)
1243 (19.3)
331 (5.1)
28.2 (25, 32)
71 (§ 12.7)

193 (45.1)
219 (51.2)
16 (3.7)
28.3 (24, 33)
73 (§ 14.3)

178 (§ 27)

177 (§ 27.3)

179 (§ 26.5)

176 (§ 27.8)

177 (§ 33.7)

10,766 (21.5)
33,844 (67.5)
24,202 (48.3)
21,325 (42.5)
5092 (10.2)

2837 (21.8)
8115 (62.5)
5110 (39.3)
6064 (46.7)
1243 (9.6)

5891 (19.5)
19,977 (66)
15,126 (50)
12,544 (41.5)
2744 (9.1)

1810 (28.1)
5332 (82.7)
3765 (58.4)
2534 (39.3)
983 (15.2)

228 (53.3)
420 (98.1)
201 (47)
183 (42.8)
122 (28.5)

6422 (12.8)

1486 (11.4)

3485 (11.5)

1305 (20.2)

146 (34.1)

2288 (4.6)

510 (3.9)

1265 (4.2)

486 (7.5)

27 (6.3)

1632 (3.3)

309 (2.4)

852 (2.8)

432 (6.7)

39 (9.1)

7851 (15.7)
14,457 (28.8)
17,931 (35.8)
9882 (19.7)

1595 (12.3)
3652 (28.1)
4937 (38)
2806 (21.6)

4119 (13.6)
8452 (27.9)
11220 (37.1)
6463 (21.4)

1895 (29.4)
2229 (34.6)
1718 (26.6)
607 (9.4)

242 (56.5)
124 (29)
56 (13.1)
6 (1.4)

50,121
Age (years)
Female sex
Race
White
Black
Other
BMI (Kg/m2)
Resting heart rate
(beats per minute)
Peak systolic blood
pressure (mm Hg)
Medical history
Diabetes
Hypertension
Hyperlipidemia
History of smoking
Prior myocardial
infarction
Prior coronary artery
disease
Prior coronary
artery
angioplasty
Prior CABG
Metabolic equivalents
of task achieved:
METs <6
METs 6-<10
METs 10-<12
METs ≥12

Stage 1 CKD eGFR ≥90
mL/min/1.73 m2
12,990 (25.9)

BMI = body mass index; CABG = coronary artery bypass grafting; CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate;
METs = metabolic equivalents of task.
All categorical data presented as total number (%), and continuous data presented as mean (standard deviation) or median (25th, 75th), as appropriate.

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on October 18, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

Chu et al
Table 2

Chronic Kidney Disease and Cardiorespiratory Fitness

5

Medication Use Across Chronic Kidney Disease Stages
Stage 2 CKD
eGFR 60-89 mL/min/
1.73 m2
30,254 (60.4)

Stage 3 CKD
eGFR 30-59 mL/min/
1.73 m2
6449 (12.9)

Stage 4/5 CKD
eGFR <30 mL/min/
1.73 m2
428 (0.9)

P Value

50,121

Stage 1 CKD
eGFR ≥90 mL/min/
1.73 m2
12,990 (25.9)

11,260 (22.5)
6903 (13.8)

2549 (19.6)
1494 (11.5)

6351 (21)
3843 (12.7)

2193 (34)
1370 (21.2)

167 (39)
196 (45.8)

< .001
< .001

10,235 (20.4)
1659 (3.3)
10,698 (21.3)
10,529 (21)
13,111 (26.2)

2262 (17.4)
308 (2.4)
2123 (16.3)
2499 (19.2)
2549 (19.6)

5877 (19.4)
923 (3.1)
6000 (19.8)
6117 (20.2)
7997 (26.4)

1945 (30.2)
386 (6)
2387 (37)
1779 (27.6)
2418 (37.5)

151 (35.5)
42 (9.8)
188 (43.9)
134 (31.3)
147 (34.3)

< .001
< .001
< .001
< .001
< .001

1957 (3.9)

523 (4)

924 (3.1)

419 (6.5)

91 (21.3)

< .001

Total

Medications:
b-blocker
Ca channel
blocker
ACE inhibitor
ARBs
Diuretics
Aspirin
Cholesterol-lowering agents
Insulin

−

ACE = angiotensin-converting enzyme; ARBs = angiotensin receptor blockers; Ca = calcium; CKD = chronic kidney disease; eGFR = estimated glomerular
filtration rate.
All data are categorical and they presented as total number (%).

Figure 1 Annualized mortality incidence rates (%) for the association of estimated glomerular filtration rates
(GFR) and mortality stratified by cardiorespiratory fitness assessed using metabolic equivalents of task (Metabolic
equivalents of task; unadjusted data).
CKD = chronic kidney disease; METs = metabolic equivalents of task.

There was an incrementally higher risk of mortality with
lower metabolic equivalents of task achieved across each
chronic kidney disease category. For example, the annualized
death rate was 10.4% vs 0.1% for metabolic equivalents of
task <6 vs ≥12 among patients with chronic kidney disease
stage 4/5; P < .001 (Figure 1). The cumulative risk of mortality
and major adverse cardiovascular events was higher among
patients with chronic kidney disease stage 3 and greater, and
also higher among those who did not achieve 85% of predicted
target heart rate. Patients with at least chronic kidney disease
stage 3 who did not achieve target heart rate had the worst survival for these outcomes (Figure 2).

Multivariate Survival Analysis
There was a significantly lower risk of overall adjusted
mortality with higher metabolic equivalents of task
achieved among patients with chronic kidney disease
(Table 3). For example, the adjusted hazard ratio (HR)
(95% confidence interval [CI]) among those who attained
≥12 metabolic equivalents of task, compared with those
who attained <6, was 0.18 (0.12-0.28). Each 1 unit higher
metabolic equivalents of task was associated with a significant 15% reduction in all-cause mortality (HR 0.85; 95%
CI, 0.84-0.87).

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on October 18, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

ARTICLE IN PRESS

The American Journal of Medicine, Vol 000, No 000, && 2021

6

Figure 2 Kaplan-Meier curves for the interplay of renal insufficiency (chronic kidney disease stage 3 to 5) and
achieving target heart rate with the outcomes of (A) cardiac mortality and (B) myocardial infarction, or cardiac
mortality.
CKD = chronic kidney disease; HR = heart rate; MACE = major adverse cardiovascular events.

Mortality Risk Discrimination and
Reclassification
Metabolic equivalents of task improved the discriminatory
ability for mortality prediction when added to traditional
risk factors and estimated glomerular filtration rate (AUC
0.7996; 95% CI, 0.789-0.810 vs 0.759; 95% CI, 0.7480.770, respectively, P < .001). The addition of metabolic
equivalents of task to traditional risk factors resulted in significant reclassification of mortality (6% for events, 5% for
non-events: NRI = 0.13, P < .001).

Sensitivity Analyses
The inclusion of stage 2 in our definition of chronic kidney
disease demonstrated similar results with a graded inversed
association between higher metabolic equivalents of task
and lower risk of all-cause mortality (Supplementary
Table 1). In general, we found a consistent association
between metabolic equivalents of task and all-cause mortality in all chronic kidney disease stages, with no evidence of
effect modification (P for interaction = .49) (Supplementary
Table 2). Failure to achieve target heart rate was associated
with lower survival in the adjusted model (HR 0.79; 95%
CI, 0.71-0.88).

Table 3 Association Between Metabolic Equivalents of Task
Achieved and All-Cause Mortality in Patients with Chronic Kidney Disease Stage 3-5: Hazard Ratio (95% Confidence Interval)

Cardiorespiratory fitness
categories
<6 METs
6-<10 METs
10-<12 METs
≥12 METs
P trend across categories
as ordinal variable
METs per 1 unit
P value

Model 1

Model 2

1.00 (ref)
0.46 (0.42-0.51)
0.25 (0.21-0.29)
0.09 (0.06-0.14)
< .001

1.00 (ref)
0.60 (0.54-0.67)
0.39 (0.33-0.46)
0.18 (0.12-0.28)
< .001

0.79 (0.77-0.80)
< .001

0.85 (0.84-0.87)
< .001

METs = metabolic equivalents of task.
Model 1 adjusted for age, sex, and race.
Model 2 adjusted for model 1 and hypertension, diabetes, dyslipidemia, body mass index categories, history of coronary artery disease, history of smoking, statin use, aspirin use, beta-blocker use, failure to
achieve target heart rate, and estimated glomerular filtration rate.

DISCUSSION
In a large (n = 50,121) and diverse retrospective cohort of
patients who completed a clinically indicated stress test, we
found that cardiorespiratory fitness was independently and

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on October 18, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

Chu et al

ARTICLE IN PRESS

Chronic Kidney Disease and Cardiorespiratory Fitness

inversely associated with mortality across the spectrum of
chronic kidney disease stages. We also showed that cardiorespiratory fitness improves risk discrimination and reclassification of mortality events.
Our findings are consistent with prior studies showing
that cardiorespiratory fitness predicts mortality and adverse
events among patients with chronic kidney disease.25,26
Gulati et al27 found that cardiorespiratory fitness improves
mortality risk prediction among patients with chronic kidney disease, although the analysis included only women,
whereas our large study cohort included both men and
women and was ethnically diverse. In a separate study,
Howden et al19 noted that patients with chronic kidney disease and low cardiorespiratory fitness, as measured by peak
maximal oxygen intake, had increased aortic stiffness, left
ventricular afterload, and overall cardiovascular risk burden. In addition, the study found that chronic kidney disease
was associated with lower levels of fitness. However, the
cohort in the analysis was small, with only 136 patients
with chronic kidney disease stage 3 or 4, and did not have
follow-up for long-term outcomes.
We found that patients with renal dysfunction who had
not achieved target heart rate had the worst survival. Previous studies have demonstrated an association between autonomic imbalance, adverse cardiovascular outcomes, and
incidence of chronic kidney disease.28 Largely determined
by sympathetic and parasympathetic activity, heart rate is
the biggest driver of VO2 increase during exercise, along
with maximal stroke volume and maximal arteriovenous
oxygen difference.29 Chronic kidney disease leads to muscle catabolism through means of anorexia, uremia, and
inflammation, and worsening renal function may lead to
further inactivity and risk factor accumulation.30 Improved
cardiorespiratory fitness may exert a survival advantage by
not only attenuating traditional risk factors, but also through
beneficial impact on the hematologic, vascular, and
immune systems.31-35
Future research should assess the effect of interventions
aimed at improving cardiorespiratory fitness among patients
with chronic kidney disease by examining change in cardiovascular risk factor profile, renal function, VO2 max and oxygen
consumption, lean body mass, markers of inflammation, endocardial dysfunction, myocardial injury, and subclinical atherosclerosis. Such prospective studies could identify mechanisms
by which cardiorespiratory fitness can affect survival among
patients with chronic kidney disease. Additional research
should examine the utility of incorporating cardiorespiratory
fitness, if available, into clinical scoring models by validating
our findings in other datasets.36,37
Our results have important clinical implications.
Because physical activity is the main lifestyle factor that
can modify cardiorespiratory fitness, participating in at least
30 minutes per day of moderate-intensity exercise may
carry a significant benefit to overall health and
mortality.38,39 Improved cardiorespiratory fitness may exert
a protective effect on reducing burden of cardiovascular
risk factors and is associated with a lower incidence of
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coronary heart disease, stroke, cancer, and mortality.5,20
One metabolic equivalent of task is approximately equivalent to the resting metabolic rate, or the energy spent while
sitting quietly. An additional metabolic equivalent is a multiple of this, and at the low end of the spectrum could be
making your bed or folding, compared with sitting quietly
or washing your car. At the higher end of the spectrum, it is
the difference between running at a pace of an 8-minute
mile and a 7-minute mile. It is important to counsel the
most sedentary patients to perform at least moderate activities (>6 metabolic equivalents of task) such as biking, running, swimming, or participation in sports. Our results add
to the already robust body of evidence related to the benefits
of physical activity and reinforce the 2016 American Heart
Association Statement on cardiorespiratory fitness as a clinical vital sign.
Our results should be interpreted in the setting of several
key limitations:

1) The FIT Project is a retrospective cohort of patients
who were recruited at a single health system with distinct practice norms, which may limit generalizability
to other health care systems.
2) Temporal changes in risk factors and medication use
may hinder generalizability of our results to modernday populations.
3) Patients included in the current analysis underwent a
clinically indicated stress test to rule out coronary
artery disease. This raises the potential of selection
bias and could attenuate the clinical impact of our
results.
4) Furthermore, those with preexisting electrocardiogram abnormalities or significant functional limitations, prevalent in patients with advanced chronic
kidney disease, likely underwent diagnostic tests other
than exercise stress testing to rule out coronary ischemia. As patients who underwent pharmacological
stress testing or other imaging modalities were
excluded from the dataset, we could not compare our
results with this group.
5) We only measured cardiorespiratory fitness and estimated glomerular filtration rate at a single point in
time, but changes in fitness or renal impairment over
time are also significant.
6) While chronic kidney disease guidelines both mandate
use of angiotensin receptor blockers or angiotensin-converting enzyme inhibitor regardless of diabetes, a relatively small proportion of the cohort was compliant with
these medications due to a significant portion of the study
cohort preceding modern guidelines.
7) Estimated glomerular filtration rate was estimated
using the Modification of Diet in Renal Disease equation as opposed to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, which
may be more accurate.
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8) We could not determine whether patients were on dialysis in those with chronic kidney disease stage 4/5, as this
information was not available in the FIT database.
9) Our chronic kidney disease population was mostly
stage 3, as opposed to 4/5, which may limit generalizability of results to patients with more advanced renal
dysfunction. However, our results stratifying by
chronic kidney disease stage showed consistent results
for improved survival with cardiorespiratory fitness
regardless of renal function.
10) Lastly, many but not all chronic kidney diseaserelated factors contributing to cardiovascular risk
were included, which could result in residual confounding. For example, calcium phosphorus product,
which becomes more relevant in later stages of
chronic kidney disease, was not included.
11) We could not evaluate mechanistic pathways underlying the association between cardiorespiratory fitness
and all-cause mortality given the observational nature
of this study.
In conclusion, we observed that higher cardiorespiratory fitness is inversely and independently associated with all-cause
mortality in patients with chronic kidney disease. Cardiorespiratory fitness may help reclassify the risk of mortality and may
inform treatment decisions in this high-risk group.
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Supplementary Table 1 Association Between Metabolic
Equivalents of Task Achieved and All-Cause Mortality in Patients
with Chronic Kidney Disease Stages 2-5: Hazard Ratio (95% Confidence Interval)

Cardiorespiratory fitness
categories
<6 METs
6-<10 METs
10-<12 METs
≥12 METs
P trend across categories
as ordinal variable

Model 1

Model 2

1.00 (ref)
0.49 (0.46-0.52)
0.26 (0.23-0.28)
0.14 (0.12-0.16)
< .001

1.00 (ref)
0.61 (0.57-0.65)
0.38 (0.35-0.41)
0.23 (0.19-0.27)
< .001

METs = metabolic equivalents of tasks.
Model 1 adjusted for age, sex, and race.
Model 2 adjusted for model 1 and hypertension, diabetes, dyslipidemia, body mass index categories, history of coronary artery disease, history of smoking, statin use, aspirin use, beta blocker use, failure to
achieve target heart rate, and estimated glomerular filtration rate

Supplementary Table 2 Association Between Metabolic Equivalents of Task Achieved and All-Cause Mortality Stratifying by Chronic Kidney Disease Stage: Hazard Ratio (95% Confidence Interval)
Stage 1 CKD
Stage 2 CKD
Stage 3 CKD
Stage 4/5 CKD
eGFR ≥90 mL/min/1.73 m2 eGFR 60-89 mL/min/1.73 m2 eGFR 30-59 mL/min/1.73 m2 eGFR <30 mL/min/1.73 m2
Cardiorespiratory fitness
categories
<6 METs
6-<10 METs
10-<12 METs
≥12 METs
P trend across categories as ordinal
variable
P for interaction = .27
METs per 1 unit
P value
P for interaction = .49

1.00 (ref)
0.57 (0.50-0.66)
0.40 (0.34-0.48)
0.27 (0.20-0.35)
< .001

1.00 (ref)
0.63 (0.58-0.69)
0.39 (0.35-0.44)
0.26 (0.22-0.31)
< .001

1.00 (ref)
0.61 (0.54-0.68)
0.40 (0.34-0.48)
0.18 (0.12-0.28)
< .001

1.00 (ref)
0.62 (0.46-0.83)
0.29 (0.16-0.52)
0.65 (0.15-2.83)
< .001

0.86 (0.84-0.88)
< .001

0.86 (0.85-0.88)
< .001

0.86 (0.84-0.87)
< .001

0.86 (0.81-0.91)
< .001

CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; METs = metabolic equivalents of task.
Model 1 adjusted for age, sex, and race.
Model 2 adjusted for model 1 and hypertension, diabetes, dyslipidemia, body mass index categories, history of coronary artery disease, history of smoking, statin use, aspirin use, beta-blocker use, failure to achieve target heart rate, and estimated glomerular filtration rate.
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